[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![raghavwadhwa Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::100281231.png) Raghav Wadhwa [@raghavwadhwa](/creator/twitter/raghavwadhwa) on x 97.1K followers
Created: 2025-07-19 12:55:06 UTC

🔹Aurobindo targets high single-digit revenue growth in FY26 (ex-Revlimid) with stable EBITDA margins. Growth to be led by Europe, US launches, injectables, and China/Vizag plants. Pen-G may contribute partially, biosimilar ramp-up starts H2, and full scale is expected by FY30.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946554390489526753/c:line.svg)

**Related Topics**
[h2](/topic/h2)
[quarterly earnings](/topic/quarterly-earnings)
[$auropharmans](/topic/$auropharmans)

[Post Link](https://x.com/raghavwadhwa/status/1946554390489526753)